The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Can peripheral blood MRD monitoring supplement bone marrow monitoring?
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, briefly discusses how peripheral blood monitoring of measurable residual disease (MRD) in multiple myeloma (MM) may be able to supplement MRD testing using bone marrow aspirates. There is an opportunity to use peripheral blood MRD assays to reduce the number of times invasive bone marrow testing is performed, especially in patients under observation or undergoing less intensive stages of treatment. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
